Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations.

e20074Background: It is unclear about the clinical outcome of the combination of icotinib and rh-endostatin (Endostar) in treating advanced non-small cell lung cancer (NSCLC) patients harboring epi...